stockportfolio.pro
Stocks / AMRX vs BLLN
AMRX vs BLLN
Amneal Pharmaceuticals, Inc. and BillionToOne, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Amneal Pharmaceuticals, Inc. (AMRX) | BillionToOne, Inc. (BLLN) | |
|---|---|---|
| Market cap | $4.9B | $4.6B |
| Revenue (latest FY) | $3.02B | $305.11M |
| Net income (latest FY) | $72.06M | $7.45M |
| Revenue growth (5y CAGR) | 8.7% | 106.2% |
| Net margin | 2.4% | 2.4% |
| Return on equity | -101.8% | 1.6% |
| P/E ratio | 41.3 | 182.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMRX — free Open BLLN — freeFrequently asked questions
Which is bigger, AMRX or BLLN?
Amneal Pharmaceuticals, Inc. is larger by market capitalization — $4.9B versus $4.6B.
Which grows faster, AMRX or BLLN?
Over the last five fiscal years, BillionToOne, Inc. grew revenue faster — 106.2%/yr versus 8.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.